Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today. The findings confirm clinical trial data and demonstrate that oral anticoagulation with rivaroxaban, a direct Factor Xa inhibitor, is safe and effective for stroke prevention in patients with AF at both high- and low-risk of thromboembolic events.
↧